Sultopride

Sultopride is a selective antagonist of dopamine D2 receptor.

Signaling Pathways >> GPCR/G Protein >> Dopamine Receptor

Signaling Pathways >> Neuronal Signaling >> Dopamine Receptor

Research Areas >> Neurological Disease

Dopamine D2 receptor[1]

Sultopride is a selective antagonist of dopamine D2 receptor. DOPAC and HVA levels in the striatum, the nucleus accumbens and the medial prefrontal cortex are higher in the rats treated with Sultopride and sulpiride than those of the controls. In the striatum, DOPAC and HVA levels are higher in the Sultopride-treated rats than the sulpiride-treated rats (p<0.05). In the nucleus accumbens, DOPAC levels are higher in the Sultopride-treated rats than sulpiride treated rats (p<0.05). In the Sultopride-treated rats, DOPAC and HVA levels are higher in the striatum or in the nucleus accumbens than in the medial prefrontal cortex (p<0.05)[1].

Thirty-six male Sprague-Dawley rats weighing 180 to 220 g are used in this study. The rats are divided into three groups of 6 each. One group is intraperitoneally injected with Sultopride (100 mg/kg body weight), the second group with sulphide (100 mg/kg body weight), and the third group with normal saline. One hundred minutes after the initial treatments, apomorphine (0.1 mg/kg body weight, dissolved in saline ad libitum) is administered subcutaneously to the three groups, and 20 minutes later the rats are sacrificed. The third group serves as controls[1].

[1]. Moriuchi K, et al. Differences in effects of sultopride and sulpiride on dopamine turnover in rat brain. Neurochem Res. 1995 Jan;20(1):95-9.

CB-154 mesylate | SCH 23390 hydrochloride | Levodopa | Cabergoline | Thioridazine hydrochloride | Brexpiprazole | Domperidone | Trifluoperazine dihydrochloride | pimozide | Risperidone | SKF38393 HCl | Cariprazine | SERTINDOLE | Fluphenazine (dihydrochloride) | Nomifensine

DATA ITEMS CITED :

4

MOLECULAR FORMULA :

C17-H26-N2-O4-S

MOLECULAR WEIGHT :

354.51

WISWESSER LINE NOTATION :

T5NTJ A2 B1MVR BO1 DSW2

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Oral

SPECIES OBSERVED :

Rodent - mouse

DOSE/DURATION :

665 mg/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

REFERENCE :

DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 10,758,1985

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Intraperitoneal

SPECIES OBSERVED :

Rodent - mouse

DOSE/DURATION :

300 mg/kg

TOXIC EFFECTS :

Behavioral - rigidity (including catalepsy)

REFERENCE :

EJMCA5 European Journal of Medicinal Chemistry--Chimie Therapeutique. (Editions Scientifiques Elsevier, 29 rue Buffon, F-75005, Paris, France) V.9- 1974- Volume(issue)/page/year: 17,437,1982 ** REPRODUCTIVE DATA **

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Subcutaneous

DOSE :

793 mg/kg

SEX/DURATION :

female 25 day(s) pre-mating

TOXIC EFFECTS :

Reproductive - Maternal Effects - ovaries, fallopian tubes Reproductive - Maternal Effects - uterus, cervix, vagina

REFERENCE :

THERAP Therapie. (Doin, Editeurs, 8, Place de l'Odeon, F-75006 Paris, France) V.1- 1946- Volume(issue)/page/year: 30,231,1975

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Subcutaneous

DOSE :

51300 ug/kg

SEX/DURATION :

female 19 day(s) pre-mating

TOXIC EFFECTS :

Reproductive - Maternal Effects - menstrual cycle changes or disorders

REFERENCE :

THERAP Therapie. (Doin, Editeurs, 8, Place de l'Odeon, F-75006 Paris, France) V.1- 1946- Volume(issue)/page/year: 30,231,1975